{
  "timeinms": 1751486050680,
  "time": 1751486050,
  "headline": "Drug-Free Nasal Spray LUCA V-Defense Creates a Protective Shield Against Viruses and Allergies",
  "language": "en-US",
  "attribn": "PRN",
  "storydate": "2025-07-02 19:54:10.665",
  "takedate": "2025-07-02 19:54:10.665",
  "urgency": 3,
  "pubStatus": "stat:usable",
  "messagetype": "news_prnus",
  "pnac": "nPnkp7Yza",
  "mimetype": "text/plain",
  "revlevel": 0,
  "guid": "tag:reuters.com,2025-06-27:newsml_Pnkp7Yza:1",
  "urn": "urn:newsml:reuters.com:20250627:nPnkp7Yza",
  "takeno": 1,
  "prodcode": "NP:CNR NP:PRN",
  "audiences": "",
  "subjects": "B:148 B:149 B:153 B:156 B:159 E:1 E:40 E:6Q G:1 G:4 G:6 G:6J G:6S G:9 G:AE G:K G:S M:1QD M:1WN M:2CM M:2CN M:2CP M:2CQ M:2CR M:2CS M:2CT M:2CU M:2CV M:2CY M:2D1 M:2DY M:32 M:Z N2:AMERS N2:ASIA N2:ASXPAC N2:BACT N2:CMPNY N2:CPROD N2:EASIA N2:EMRG N2:HECA N2:HLTHSE N2:HPAS N2:INDU N2:KR N2:LEN N2:MRCH N2:NAMER N2:NEWR N2:PHMR N2:PRDLCH N2:PRIVT N2:SRVCS N2:US N2:USANY P:5083780811",
  "nameditemcodes": "",
  "nameditems": "",
  "updatetype": 2,
  "messageid": "Pnkp7Yza__2507022ZEYZhg586xThLDnH2ukOkahJSmqHRKFVEYdH9",
  "len": 24405,
  "compression": "none",
  "data": "<?xml version=\"1.0\" encoding=\"utf-8\" standalone=\"no\" ?><newsMessage xmlns=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:rtr=\"http://www.reuters.com/ns/2003/08/content\" xmlns:x=\"http://www.w3.org/1999/xhtml\" xmlns:xs=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xsi:schemaLocation=\"http://iptc.org/std/nar/2006-10-01/ ../ref/RSF_1.6.6-spec-All-Power_1.xsd http://www.reuters.com/ns/2003/08/content ../ref/rtr_1.6.6.xsd http://www.w3.org/1999/xhtml ../ref/xhtml1-strict.xsd \"><header><sent>2025-07-02T19:54:10.665Z</sent><sender>reuters.com</sender><transmitId>tag:reuters.com,2025-06-27:newsml_Pnkp7Yza:1</transmitId><priority>3</priority><destination qcode=\"NP:CNR\"/><destination qcode=\"NP:PRN\"/><channel>TXT</channel></header><itemSet><newsItem conformance=\"power\" guid=\"tag:reuters.com,2025-06-27:newsml_Pnkp7Yza\" standard=\"NewsML-G2\" standardversion=\"2.18\" version=\"1\"><catalogRef href=\"http://xml.media.reuters.com/g2-standards/catalogs/ReutersMedia_G2-Standards-Catalog_v1.xml\"/><rightsInfo><copyrightHolder literal=\"PR Newswire Association,LLC. All Rights Reserved.\"/><copyrightNotice>Copyright (c) 2025 PR Newswire Association,LLC. All Rights Reserved.</copyrightNotice></rightsInfo><itemMeta><itemClass qcode=\"ninat:text\" rtr:msgType=\"S\"/><provider literal=\"reuters.com\"/><versionCreated>2025-07-02T19:54:10.665Z</versionCreated><firstCreated>2025-07-02T19:54:10.665Z</firstCreated><pubStatus qcode=\"stat:usable\"/><role qcode=\"itemRole:N\"/><generator versioninfo=\"1.0.56798\">_UCDP:parsn_prnus_10.51.13.14_1.2.56798:</generator><title>Drug-Free Nasal Spray LUCA V-Defense Creates a Protective Shield Against Viruses and Allergies</title><signal qcode=\"prodId:TXT\"/><signal qcode=\"pmt:text\"/><signal qcode=\"edStat:N\"/><expires>2026-10-02T19:54:10.665Z</expires><link rel=\"irel:seeAlso\" residref=\"urn:newsml:reuters.com:20250627:nPnkp7Yza\"/><rtr:internal><itemMetaExtProperty rel=\"legacyField:FID_TABTEXT\" value=\"T\" valuedatatype=\"xs:string\"/><itemMetaExtProperty rel=\"extCptRel:hasRsfVersion\" value=\"1.6.6\" valuedatatype=\"xs:string\"/></rtr:internal><rtr:versionedId guid=\"tag:reuters.com,2025-06-27:newsml_Pnkp7Yza:1\"/></itemMeta><contentMeta><urgency>3</urgency><infoSource qcode=\"NS:PRN\" role=\"cRole:source\"/><infoSource qcode=\"NS:PRN\" role=\"cRole:origProv\"/><creator qcode=\"NS:PRN\" role=\"cRole:source\"/><contributor qcode=\"NS:RFT\" role=\"cRole:enhancer\"/><audience creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"A1\" qcode=\"NP:CNR\" why=\"why:inferred\"/><audience creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"A2\" qcode=\"NP:PRN\" why=\"why:inferred\"/><altId type=\"idType:USN\">Pnkp7Yza</altId><altId type=\"idType:storyId\">urn:newsml:reuters.com:20250627:nPnkp7Yza</altId><language tag=\"en\"/><subject confidence=\"100\" creator=\"sys:UCDP\" id=\"S1\" qcode=\"B:148\" relevance=\"98\" why=\"why:direct\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S2\" qcode=\"B:149\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" id=\"S3\" qcode=\"B:153\" relevance=\"98\" why=\"why:direct\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S4\" qcode=\"B:156\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" id=\"S5\" qcode=\"B:159\" relevance=\"98\" why=\"why:direct\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S6\" qcode=\"E:1\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S7\" qcode=\"E:40\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" id=\"S8\" qcode=\"E:6Q\" relevance=\"98\" why=\"why:direct\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S9\" qcode=\"G:1\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S10\" qcode=\"G:4\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S11\" qcode=\"G:6J\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" id=\"S12\" qcode=\"G:6S\" relevance=\"98\" why=\"why:direct\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S13\" qcode=\"G:6\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S14\" qcode=\"G:9\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" id=\"S15\" qcode=\"G:AE\" relevance=\"98\" why=\"why:direct\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S16\" qcode=\"G:K\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S17\" qcode=\"G:S\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S18\" qcode=\"M:1QD\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S19\" qcode=\"M:1WN\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S20\" qcode=\"M:2CM\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S21\" qcode=\"M:2CN\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S22\" qcode=\"M:2CP\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S23\" qcode=\"M:2CQ\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S24\" qcode=\"M:2CR\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S25\" qcode=\"M:2CS\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S26\" qcode=\"M:2CT\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S27\" qcode=\"M:2CU\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S28\" qcode=\"M:2CV\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S29\" qcode=\"M:2CY\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S30\" qcode=\"M:2D1\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S31\" qcode=\"M:2DY\" relevance=\"80\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S32\" qcode=\"M:32\" relevance=\"98\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" how=\"howextr:tool\" id=\"S33\" qcode=\"M:Z\" relevance=\"80\" why=\"why:associated\"/><subject confidence=\"100\" creator=\"sys:UCDP\" id=\"P1\" qcode=\"P:5083780811\" relevance=\"80\" why=\"why:direct\"/><slugline>LUCA</slugline><headline dir=\"ltr\" xml:lang=\"en-us\">Drug-Free Nasal Spray LUCA V-Defense Creates a Protective Shield Against Viruses and Allergies</headline><contentMetaExtProperty rel=\"extCptRel:hasRestrictedHeadlineLang\" value=\"en\" valuedatatype=\"xs:string\"/><contentMetaExtProperty rel=\"extCptRel:hasRestrictedContentLang\" value=\"en\" valuedatatype=\"xs:string\"/><rtr:internal/></contentMeta><assert qcode=\"NP:CNR\"><type qcode=\"cptType:15\"/></assert><assert qcode=\"NP:PRN\"><type qcode=\"cptType:15\"/></assert><assert qcode=\"B:148\"><sameAs qcode=\"N2:HECA\"/><name>Healthcare (TRBC level 1)</name><type qcode=\"cptType:2\"/></assert><assert qcode=\"B:149\"><sameAs qcode=\"N2:HLTHSE\"/><name>Healthcare Services &amp; Equipment (TRBC level 2)</name><type qcode=\"cptType:2\"/></assert><assert qcode=\"B:153\"><sameAs qcode=\"N2:HPAS\"/><name>Healthcare Providers &amp; Services (TRBC level 3)</name><type qcode=\"cptType:2\"/></assert><assert qcode=\"B:156\"><sameAs qcode=\"N2:PHMR\"/><name>Pharmaceuticals &amp; Medical Research (TRBC level 2)</name><type qcode=\"cptType:2\"/></assert><assert qcode=\"B:159\"><sameAs qcode=\"N2:MRCH\"/><name>Biotechnology &amp; Medical Research (TRBC level 4)</name><type qcode=\"cptType:2\"/></assert><assert qcode=\"E:1\"><sameAs qcode=\"N2:BACT\"/><name>Corporate Events</name><type qcode=\"cptType:4\"/></assert><assert qcode=\"E:40\"><sameAs qcode=\"N2:CPROD\"/><name>Products / Services</name><type qcode=\"cptType:4\"/></assert><assert qcode=\"E:6Q\"><sameAs qcode=\"N2:PRDLCH\"/><name>Product Launches</name><type qcode=\"cptType:85\"/></assert><assert qcode=\"G:1\"><sameAs qcode=\"N2:EMRG\"/><name>Emerging Market Countries</name><type qcode=\"cptType:5\"/></assert><assert qcode=\"G:4\"><sameAs qcode=\"N2:AMERS\"/><name>Americas</name><type qcode=\"cptType:5\"/></assert><assert qcode=\"G:6J\"><sameAs qcode=\"N2:US\"/><name>United States</name><type qcode=\"cptType:5\"/></assert><assert qcode=\"G:6S\"><sameAs qcode=\"N2:USANY\"/><name>New York</name><type qcode=\"cptType:5\"/></assert><assert qcode=\"G:6\"><sameAs qcode=\"N2:EASIA\"/><name>East Asia</name><type qcode=\"cptType:5\"/></assert><assert qcode=\"G:9\"><sameAs qcode=\"N2:NAMER\"/><name>North America</name><type qcode=\"cptType:5\"/></assert><assert qcode=\"G:AE\"><sameAs qcode=\"N2:KR\"/><name>South Korea</name><type qcode=\"cptType:5\"/></assert><assert qcode=\"G:K\"><sameAs qcode=\"N2:ASIA\"/><name>Asia / Pacific</name><type qcode=\"cptType:5\"/></assert><assert qcode=\"G:S\"><sameAs qcode=\"N2:ASXPAC\"/><name>Asia</name><type qcode=\"cptType:5\"/></assert><assert qcode=\"M:1QD\"><name>Suggested Sources</name><type qcode=\"cptType:40\"/></assert><assert qcode=\"M:1WN\"><sameAs qcode=\"N2:SRVCS\"/><name>Services</name><type qcode=\"cptType:2\"/></assert><assert qcode=\"M:2CM\"><name>Investment Bankers</name><type qcode=\"cptType:40\"/></assert><assert qcode=\"M:2CN\"><name>Research Analysts and Portfolio Managers</name><type qcode=\"cptType:40\"/></assert><assert qcode=\"M:2CP\"><name>Wealth Managers</name><type qcode=\"cptType:40\"/></assert><assert qcode=\"M:2CQ\"><name>Equities</name><type qcode=\"cptType:40\"/></assert><assert qcode=\"M:2CR\"><name>Fixed Income</name><type qcode=\"cptType:40\"/></assert><assert qcode=\"M:2CS\"><name>Foreign Exchange</name><type qcode=\"cptType:40\"/></assert><assert qcode=\"M:2CT\"><name>Commodities</name><type qcode=\"cptType:40\"/></assert><assert qcode=\"M:2CU\"><name>Academia</name><type qcode=\"cptType:40\"/></assert><assert qcode=\"M:2CV\"><name>Developers</name><type qcode=\"cptType:40\"/></assert><assert qcode=\"M:2CY\"><name>Europe</name><type qcode=\"cptType:40\"/></assert><assert qcode=\"M:2D1\"><name>North America</name><type qcode=\"cptType:40\"/></assert><assert qcode=\"M:2DY\"><sameAs qcode=\"N2:PRIVT\"/><name>Private Company News</name><type qcode=\"cptType:82\"/></assert><assert qcode=\"M:32\"><sameAs qcode=\"N2:NEWR\"/><name>News Announcements</name><type qcode=\"cptType:10\"/></assert><assert qcode=\"M:Z\"><sameAs qcode=\"N2:CMPNY\"/><name>Company News</name><type qcode=\"cptType:82\"/></assert><assert qcode=\"P:5083780811\"><name>Luca AICell Inc</name><type qcode=\"cptType:8\"/></assert><derivedFrom idrefs=\"A1\" qcode=\"NP:CNR\"/><derivedFrom idrefs=\"A2\" qcode=\"NP:PRN\"/><derivedFrom idrefs=\"A1 A2\"><broader qcode=\"mduAction:enrichMetadata\"/><related rel=\"extCptRel:hasWorker\"><related qcode=\"sys:UCDP\" rel=\"skos:broader\"/><related qcode=\"ucdpWorker:parserConfig\" rel=\"extCptRel:hasWorkerDetail\"/></related></derivedFrom><derivedFrom idrefs=\"S2 S19\" qcode=\"B:153\"/><derivedFrom idrefs=\"S4\" qcode=\"B:159\"/><derivedFrom idrefs=\"S6 S7\" qcode=\"E:6Q\"/><derivedFrom idrefs=\"S10 S11 S14\" qcode=\"G:6S\"/><derivedFrom idrefs=\"S9 S13 S16 S17\" qcode=\"G:AE\"/><derivedFrom idrefs=\"S21\" qcode=\"NP:PRN\"/><derivedFrom idrefs=\"S18 S20 S22 S23 S24 S25 S26 S27 S28 S29 S30 S32\" qcode=\"NS:PRN\"/><derivedFrom idrefs=\"S31 S33\" qcode=\"P:5083780811\"/><derivedFrom idrefs=\"S12\" literal=\"PRN:GEOGRAPHY:New York\"/><derivedFrom idrefs=\"S15\" literal=\"PRN:GEOGRAPHY:South Korea\"/><derivedFrom idrefs=\"S5\" literal=\"PRN:INDUSTRY:BIO\"/><derivedFrom idrefs=\"S3\" literal=\"PRN:INDUSTRY:HEA\"/><derivedFrom idrefs=\"S1\" literal=\"PRN:INDUSTRY:MTC\"/><derivedFrom idrefs=\"S8\" literal=\"PRN:SUBJECT:PDT\"/><derivedFrom idrefs=\"S1 S3 S5 S8 S12 S15\"><broader qcode=\"mduAction:enrichMetadata\"/><related rel=\"extCptRel:hasWorker\"><related qcode=\"sys:RDS\" rel=\"skos:broader\"/><related qcode=\"rdsWorker:3rdpartytoRCS.txt\" rel=\"extCptRel:hasWorkerDetail\"/></related></derivedFrom><derivedFrom idrefs=\"S31 S33\"><broader qcode=\"mduAction:enrichMetadata\"/><related rel=\"extCptRel:hasWorker\"><related qcode=\"sys:RDS\" rel=\"skos:broader\"/><related qcode=\"rdsWorker:orgTable\" rel=\"extCptRel:hasWorkerDetail\"/></related></derivedFrom><derivedFrom idrefs=\"S2 S4 S6 S7 S9 S10 S11 S13 S14 S16 S17 S18 S19 S20 S21 S22 S23 S24 S25 S26 S27 S28 S29 S30 S32\"><broader qcode=\"mduAction:enrichMetadata\"/><related rel=\"extCptRel:hasWorker\"><related qcode=\"sys:RDS\" rel=\"skos:broader\"/><related qcode=\"rdsWorker:rcsExpansion\" rel=\"extCptRel:hasWorkerDetail\"/></related></derivedFrom><derivedFrom idrefs=\"P1\" literal=\"LUCA AICELL\"/><derivedFrom idrefs=\"P1\"><broader qcode=\"mduAction:enrichMetadata\"/><related rel=\"extCptRel:hasWorker\"><related qcode=\"sys:RDS\" rel=\"skos:broader\"/><related qcode=\"rdsWorker:orgTable\" rel=\"extCptRel:hasWorkerDetail\"/></related></derivedFrom><derivedFrom idrefs=\"S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 S23 S24 S25 S26 S27 S28 S29 S30 S31 S32 S33 P1\"><broader qcode=\"mduAction:enrichMetadata\"/><related rel=\"extCptRel:hasWorker\"><related qcode=\"sys:UCDP\" rel=\"skos:broader\"/><related qcode=\"ucdpWorker:relevanceRules\" rel=\"extCptRel:hasWorkerDetail\"/></related></derivedFrom><derivedFrom idrefs=\"S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 S14 S15 S16 S17 S18 S19 S20 S21 S22 S23 S24 S25 S26 S27 S28 S29 S30 S31 S32 S33 P1\"><broader qcode=\"mduAction:enrichMetadata\"/><related rel=\"extCptRel:hasWorker\"><related qcode=\"sys:UCDP\" rel=\"skos:broader\"/><related qcode=\"ucdpWorker:confidenceRules\" rel=\"extCptRel:hasWorkerDetail\"/></related></derivedFrom><contentSet><inlineXML contenttype=\"application/xhtml+xml\"><html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:xn=\"http://www.xmlnews.org/ns/\">\n\n<head>\n<meta content=\"text/html; charset=UTF-8\" http-equiv=\"Content-Type\"/>\n<title>Drug-Free Nasal Spray LUCA V-Defense Creates a Protective Shield Against Viruses and Allergies</title>\n<style type=\"text/css\">\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n</style>\n</head>\n\n<body>\n\n<div class=\"xn-newslines\">\n<h1 class=\"xn-hedline\">Drug-Free Nasal Spray LUCA V-Defense Creates a Protective Shield Against Viruses and Allergies</h1>\n<p class=\"xn-distributor\">PR Newswire</p>\n<p class=\"xn-dateline\">SEOUL, South Korea, June 27, 2025</p></div>\n\n<div class=\"xn-content\">\n\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SEOUL, South Korea</span></span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">June 27, 2025</span></span> /PRNewswire/ -- As respiratory illnesses like COVID-19, influenza, and Mycoplasma pneumonia continue to spread, the need for safe, non-pharmaceutical prevention options is growing. South Korea–based biotech firm LUCA AICELL has developed LUCA V-Defense Nasal Spray, a drug-free nasal spray designed to form a protective barrier on the nasal lining—offering a modern solution in the post-mask era.</p>\n\n    <div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n                <p>\n                        <a href=\"https://mma.prnewswire.com/media/2719487/20250527.html\" rel=\"nofollow\" target=\"_blank\">\n                    <img alt=\"LUCA V-Defense nasal spray\" src=\"https://mma.prnewswire.com/media/2719487/20250527.jpg\" title=\"LUCA V-Defense nasal spray\"/>\n                        </a>\n                </p>\n\n    </div>\n<p><b>A Physical Barrier, Not a Medication</b></p>\n<p>Unlike traditional nasal sprays that rely on steroids or antihistamines, LUCA V-Defense forms a non-medicated barrier across the nasal mucosa, the body's first line of defense against airborne pathogens. Instead of using steroids, antihistamines, or vasoconstrictors, LUCA V-Defense relies on lambda carrageenan, a natural compound extracted from red algae, and antimicrobial lipids. These ingredients coat the nasal lining, helping to prevent viruses like SARS-CoV-2 and influenza from binding to mucosal cells. Recent studies have also shown that lambda carrageenan not only possesses antiviral properties but also exhibits anti-inflammatory and anti-allergic effects, helping to reduce allergic reactions in nasal tissues and inhibit histamine release, which may contribute to the prevention of allergic rhinitis.</p>\n<p>Using LUCA's proprietary lipid nanocoating technology, the nasal spray demonstrated 99.7% antiviral efficacy within one minute in an in vitro third-party COVID-19 lab study overseas. This suggests potential across a broad spectrum of respiratory viruses.</p>\n<p><b>Rapid Adoption and International Certifications</b></p>\n<p>LUCA AICELL reports that sales of LUCA V-Defense more than tripled in the most recent quarter, signaling increasing consumer interest in preventive nasal sprays. This demand is especially strong among parents and travelers, given that no vaccine currently exists for Mycoplasma pneumonia, a common threat to children.</p>\n<p>LUCA V-Defense is classified as a medical device, not a pharmaceutical. It holds:</p>\n<ul type=\"disc\"><li><b>FDA listed</b> in <span class=\"xn-location\">the United States</span></li><li><span id=\"spanHghlt8e23\"><b>CE certified</b> in <span class=\"xn-location\">Europe</span></span></li><li><b><span id=\"spanHghlt56fd\">MFDS approved</span> </b>in <span class=\"xn-location\">South Korea</span></li></ul><p>These credentials validate its safety for daily use and its alignment with international regulatory standards.</p>\n<p><b>Safer than Steroid and Decongestant Sprays</b></p>\n<p>Many popular nasal congestion sprays contain steroids or vasoconstrictors like methazoline, which can offer fast symptom relief but are linked to rebound congestion, mucosal thinning, and reduced efficacy with long-term use.</p>\n<p>LUCA V-Defense addresses these issues with a plant-based, non-pharmaceutical formulation that's free from steroids, antihistamines, and methazoline. It is gentle enough for children, pregnant women, and individuals who suffer from seasonal allergies or chronic rhinitis. Its ease of use, a simple mist inside each nostril, makes it ideal for travel, commutes, or high-exposure environments like offices, schools, or public transit.</p>\n<p><b>Redefining Preventive Wellness in the Post-Mask Era</b></p>\n<p>As the world transitions away from masks and into a new phase of pandemic management, personal preventive tools like LUCA V-Defense are gaining relevance. Whether navigating crowded airports, allergy season, or cold and flu outbreaks, this daily-use nasal spray offers a chemical-free alternative for respiratory defense.</p>\n<p>\"The pandemic changed how we think about personal protection,\" said a LUCA AICELL spokesperson. \"LUCA V-Defense was developed not just for short-term response, but for long-term respiratory wellness. We see it as a smart, science-backed addition to modern health routines.\"</p>\n<p> </p>\n\n\n\n\n\n\n<p id=\"PURL\"><img alt=\"Cision\" height=\"12\" src=\"https://c212.net/c/img/favicon.png?sn=CN19128&amp;sd=2025-06-27\" title=\"Cision\" width=\"12\"/> View original content to download multimedia:<a href=\"https://www.prnewswire.com/news-releases/drug-free-nasal-spray-luca-v-defense-creates-a-protective-shield-against-viruses-and-allergies-302493093.html\" id=\"PRNURL\" rel=\"nofollow\" target=\"_blank\">https://www.prnewswire.com/news-releases/drug-free-nasal-spray-luca-v-defense-creates-a-protective-shield-against-viruses-and-allergies-302493093.html</a></p>\n<p>SOURCE  LUCA AICELL</p>\n\n</div>\n</body>\n</html></inlineXML><inlineData contenttype=\"text/plain\" dir=\"ltr\" xml:lang=\"en-us\"><![CDATA[For best results when printing this announcement, please click on link below:\nhttps://newsfile.hdcq.int.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250627:nPnkp7Yza&default-theme=true\n\nDrug-Free Nasal Spray LUCA V-Defense Creates a Protective Shield Against Viruses and Allergies\n\nPR Newswire\n\nSEOUL, South Korea, June 27, 2025\n\nSEOUL, South Korea, June 27, 2025 /PRNewswire/ -- As respiratory illnesses\nlike COVID-19, influenza, and Mycoplasma pneumonia continue to spread, the\nneed for safe, non-pharmaceutical prevention options is growing. South\nKorea–based biotech firm LUCA AICELL has developed LUCA V-Defense Nasal\nSpray, a drug-free nasal spray designed to form a protective barrier on the\nnasal lining—offering a modern solution in the post-mask era.\n\n(https://mma.prnewswire.com/media/2719487/20250527.html)\n\nA Physical Barrier, Not a Medication\n\nUnlike traditional nasal sprays that rely on steroids or antihistamines, LUCA\nV-Defense forms a non-medicated barrier across the nasal mucosa, the body's\nfirst line of defense against airborne pathogens. Instead of using steroids,\nantihistamines, or vasoconstrictors, LUCA V-Defense relies on lambda\ncarrageenan, a natural compound extracted from red algae, and antimicrobial\nlipids. These ingredients coat the nasal lining, helping to prevent viruses\nlike SARS-CoV-2 and influenza from binding to mucosal cells. Recent studies\nhave also shown that lambda carrageenan not only possesses antiviral\nproperties but also exhibits anti-inflammatory and anti-allergic effects,\nhelping to reduce allergic reactions in nasal tissues and inhibit histamine\nrelease, which may contribute to the prevention of allergic rhinitis.\n\nUsing LUCA's proprietary lipid nanocoating technology, the nasal spray\ndemonstrated 99.7% antiviral efficacy within one minute in an in vitro\nthird-party COVID-19 lab study overseas. This suggests potential across a\nbroad spectrum of respiratory viruses.\n\nRapid Adoption and International Certifications\n\nLUCA AICELL reports that sales of LUCA V-Defense more than tripled in the most\nrecent quarter, signaling increasing consumer interest in preventive nasal\nsprays. This demand is especially strong among parents and travelers, given\nthat no vaccine currently exists for Mycoplasma pneumonia, a common threat to\nchildren.\n\nLUCA V-Defense is classified as a medical device, not a pharmaceutical. It\nholds:\n\n * FDA listed in the United States\n * CE certified in Europe\n * MFDS approved in South Korea\nThese credentials validate its safety for daily use and its alignment with\ninternational regulatory standards.\n\nSafer than Steroid and Decongestant Sprays\n\nMany popular nasal congestion sprays contain steroids or vasoconstrictors like\nmethazoline, which can offer fast symptom relief but are linked to rebound\ncongestion, mucosal thinning, and reduced efficacy with long-term use.\n\nLUCA V-Defense addresses these issues with a plant-based, non-pharmaceutical\nformulation that's free from steroids, antihistamines, and methazoline. It is\ngentle enough for children, pregnant women, and individuals who suffer from\nseasonal allergies or chronic rhinitis. Its ease of use, a simple mist inside\neach nostril, makes it ideal for travel, commutes, or high-exposure\nenvironments like offices, schools, or public transit.\n\nRedefining Preventive Wellness in the Post-Mask Era\n\nAs the world transitions away from masks and into a new phase of pandemic\nmanagement, personal preventive tools like LUCA V-Defense are gaining\nrelevance. Whether navigating crowded airports, allergy season, or cold and\nflu outbreaks, this daily-use nasal spray offers a chemical-free alternative\nfor respiratory defense.\n\n\"The pandemic changed how we think about personal protection,\" said a LUCA\nAICELL spokesperson. \"LUCA V-Defense was developed not just for short-term\nresponse, but for long-term respiratory wellness. We see it as a smart,\nscience-backed addition to modern health routines.\"\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/drug-free-nasal-spray-luca-v-defense-creates-a-protective-shield-against-viruses-and-allergies-302493093.html\n(https://www.prnewswire.com/news-releases/drug-free-nasal-spray-luca-v-defense-creates-a-protective-shield-against-viruses-and-allergies-302493093.html)\n\nSOURCE LUCA AICELL\n\n\n\nKevin NAM, manager@amapress.co.kr\n\nPhoto: \nhttps://mma.prnewswire.com/media/2719487/20250527.jpg\n\nCopyright (c) 2025 PR Newswire Association,LLC. All Rights Reserved.]]></inlineData></contentSet></newsItem></itemSet></newsMessage>"
}